Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)
India · Delayed Price · Currency is INR | Market Cap | 1.74T +42.8% |
| Revenue (ttm) | 174.00B +42.1% |
| Net Income | 21.24B -0.7% |
| EPS | 59.12 -6.5% |
| Shares Out | n/a |
| PE Ratio | 77.20 |
| Forward PE | 59.71 |
| Dividend | 38.00 (0.83%) |
| Ex-Dividend Date | May 29, 2026 |
| Volume | 184,335 |
| Open | 4,540.00 |
| Previous Close | 4,557.00 |
| Day's Range | 4,525.30 - 4,610.90 |
| 52-Week Range | 3,532.60 - 5,250.00 |
| Beta | 0.14 |
| Analysts | Buy |
| Price Target | 5,472.79 (+19.91%) |
| Earnings Date | Oct 23, 2026 |
About Torrent Pharmaceuticals
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations in India, the United States, Brazil, Germany, Malta, and internationally. The company offers products in various therapeutic areas, including anti-diabetic, anti-microbial, cardiovascular, CNS, urology, gynecology, oncology, gastro-intestinal, nephrology, neuro-psychiatric, dermatology, pulmonology, pediatric treatments, nutritional, pain management, anti-infective, and miscellaneous... [Read more]
Financial Performance
In fiscal year 2026, Torrent Pharmaceuticals's revenue was 139.80 billion, an increase of 21.39% compared to the previous year's 115.16 billion. Earnings were 21.63 billion, an increase of 13.19%.
Financial StatementsAnalyst Summary
According to 28 analysts, the average rating for TORNTPHARM stock is "Buy." The 12-month stock price target is ₹5,473, which is an increase of 19.91% from the latest price.
News
Torrent Pharmaceuticals Transcript: Q2 26/27
Q2 revenue rose 51% and operating EBITDA rose 54%, while integration temporarily affected JB’s international sales. Cost synergies are ahead of plan, and management expects improving H2 margins and a gradual recovery in JB growth.
Torrent Pharmaceuticals Quarterly report: Q2 2027
Torrent Pharmaceuticals has published its Q2 2027 quarterly earnings report on October 23, 2026.
India's Torrent Pharma's profit slips as R&D costs outweigh domestic demand
Indian drugmaker Torrent Pharmaceuticals reported a near 10% decline in second-quarter profit on Friday, as higher spending on research and development outpaced robust demand for chronic therapies in ...
Torrent Pharmaceuticals Transcript: Q1 26/27
Revenue grew 55% YoY to INR 4,921 crore and operating EBITDA rose 61% to INR 1,664 crore, driven by strong India and international growth, successful JB merger integration, and robust cost synergies. Gross margin improved to 78%, with guidance for continued margin and revenue growth.
Torrent Pharmaceuticals Quarterly report: Q1 2027
Torrent Pharmaceuticals has published its Q1 2027 quarterly earnings report on July 30, 2026.
Torrent Pharmaceuticals Slides: Q1 2027
Torrent Pharmaceuticals has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on July 30, 2026.
JB Chemicals amalgamates with Torrent Pharma as scheme becomes effective
JB Chemicals & Pharmaceuticals Limited has officially amalgamated with Torrent Pharmaceuticals Limited, effective 8th July 2026. This development follows the approval and sanction by the National Comp...
Torrent Pharmaceuticals completes amalgamation with J.B. Chemicals
Torrent Pharmaceuticals Limited has announced the completion of its amalgamation with J.B. Chemicals & Pharmaceuticals Limited, following the approval and sanction by the National Company Law Tribunal...
Torrent Pharmaceuticals receives NCLT approval for amalgamation with J.B. Chemicals
Torrent Pharmaceuticals Limited has received the certified copy of the order from the National Company Law Tribunal (NCLT), Ahmedabad Bench, approving the Scheme of Amalgamation with J.B. Chemicals & ...
JB Chemicals receives NCLT approval for amalgamation with Torrent Pharmaceuticals
JB Chemicals & Pharmaceuticals has received a certified copy of the National Company Law Tribunal (NCLT) order sanctioning its amalgamation with Torrent Pharmaceuticals. The order, dated 6th July 2026...
JB Chemicals & Pharmaceuticals merger with Torrent Pharmaceuticals sanctioned by NCLT
The National Company Law Tribunal (NCLT) has sanctioned the Scheme of Amalgamation between JB Chemicals & Pharmaceuticals and Torrent Pharmaceuticals. This merger, approved on July 6, 2026, aligns wit...
Torrent Pharmaceuticals receives NCLT approval for merger with J. B. Chemicals
Torrent Pharmaceuticals Limited has received approval from the National Company Law Tribunal (NCLT) for its amalgamation with J. B. Chemicals & Pharmaceuticals Limited. The Ahmedabad Bench of the NCLT...
Nomura on Pharma May 2026: Torrent leads semaglutide with 19% market share, Sun gains; Alkem and Dr Reddy's lag market
Global brokerage Nomura has highlighted Torrent Pharmaceuticals as the standout performer among its India pharma coverage in May 2026, with the company recording the strongest growth in the Indian Pha...
Torrent Pharmaceuticals announces 53rd AGM via video conference on 23rd June 2026
Torrent Pharmaceuticals Limited has scheduled its 53rd Annual General Meeting (AGM) for 23rd June 2026, to be held at 9.30 A.M. (IST) through Video Conference (VC) and Other Audio-Visual Means…
Torrent Pharmaceuticals releases business responsibility and sustainability report for FY 2025-26
Torrent Pharmaceuticals has published its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, highlighting the company's commitment to sustainable and responsible ...
Torrent Pharmaceuticals shares hit 52-week today despite Q4 profit decline; revenue surges 42%
Shares of Torrent Pharmaceuticals climbed over 4% during Monday’s trading session even after the company reported a decline in fourth-quarter net profit, as investors focused on strong revenue growth,...
Here’s why Torrent Pharma shares are up 4% today
Shares of Torrent Pharmaceuticals rallied more than 4% in early trade on Monday after the company announced its financial results for the quarter ended March 2026. The pharmaceutical company reported…
Top stocks for trade today, May 25: Hindalco Industries, Torrent Pharma, Divi’s Lab, Eicher Motors, NTPC Green and more
Indian equity markets are likely to track several earnings-driven and corporate-specific developments on May 25. Companies including Hindalco Industries, Torrent Pharmaceuticals, Divi's Laboratories, ...
Torrent Pharmaceuticals Transcript: Q4 25/26
Q4 FY26 saw 42% revenue and 41% EBITDA growth, driven by JB Pharma acquisition and strong India, Brazil, and U.S. performance. Semaglutide launch led to rapid market share gains, and synergy realization from the merger is ahead of plan. India business is expected to deliver mid-teen growth in FY27.
Torrent Pharmaceuticals Slides: Q4 2026
Torrent Pharmaceuticals has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 22, 2026.
Torrent Pharmaceuticals Quarterly report: Q4 2026
Torrent Pharmaceuticals has published its Q4 2026 quarterly earnings report on May 22, 2026.
Torrent Pharmaceuticals Annual report: Q4 2026
Torrent Pharmaceuticals has published its Q4 2026 annual report on May 22, 2026.
Torrent Pharma Q4 Results: Revenue up 41.8% YoY to Rs Rs 4,197 crore, net profit falls 21.9%
Torrent Pharmaceuticals reported a mixed performance in its Q4 FY26 results, with net profit declining sharply on a year-on-year basis despite strong growth in revenue and EBITDA. The pharmaceutical m...
Torrent Pharmaceuticals proposes Rs 5,000 crore equity issuance and declares final dividend
Torrent Pharmaceuticals Limited has announced a series of significant financial decisions following its board meeting held on 22 May 2026. The company has approved its audited financial results for th...
Torrent Pharmaceuticals achieves zero observations in USFDA inspection
Torrent Pharmaceuticals has successfully concluded a USFDA inspection at its Bileshwarpura oncology facility with zero observations. The inspection, which took place from 6th April to 10th April 2026,...